Denmark-based Zealand Pharma (Zealand) has begun its Phase IIa clinical trial of dasiglucagon in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics for hypoglycaemia.

Dasiglucagon is an analogue of peptide hormone human glucagon, which is produced by alpha cells of the pancreas and released to prevent blood glucose levels dropping low, thereby ensuring a well-functioning metabolic system.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multiple-dose version of dasiglucagon is aimed to be used in a dual-hormone artificial pancreas system to better manage hypoglycaemia and offer easier options to insulin treated diabetes patients for effective management of their disease.

A dual-hormone artificial (or bionic) pancreas system, designed to automatically deliver insulin and glucagon to people with type 1 diabetes, copies the function of a healthy pancreas.

The Phase IIa trial is the fourth Phase II trial initiated by Zealand this year that intends to determine the safety, efficacy and tolerability of dasiglucagon as part of the Beta Bionics dual-hormone artificial (bionic) pancreas system in adult patients with type 1 diabetes, compared to a recombinant market glucagon.

"The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system."

The company previously entered into collaboration with Beta Bionics, which is developing the dual-hormone artificial (bionic) pancreas system based on technology conceived at Boston University.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial's principal investigator Steven Russell said: “This Phase IIa study will test the effectiveness of the stable glucagon analogue dasiglucagon in the dual-hormone bionic pancreas, comparing it with the unstable glucagon formulation that we have used in all of our previous studies.

“Demonstrating the effectiveness of a stable glucagon formulation or analogue, such as dasiglucagon, is an essential step towards making a dual-hormone bionic pancreas available to patients."

The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system.

Results from both trials are expected in the first quarter of next year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact